Current Environment:

Nancy Andrews | Overview

Nancy C. Andrews headshotExecutive Vice President and Chief Scientific Officer, Boston Children's Hospital

Dr. Andrews' appointment was announced in this letter from president and CEO Dr. Kenneth B. Churchwell.

Dear Colleagues,

After an extensive national search, and much careful consideration, it is my pleasure to introduce Nancy C. Andrews, MD, PhD, as Boston Children’s new Executive Vice President and Chief Scientific Officer.

Since Boston Children’s founding, our commitment to science, research and innovation has been one of the most important differentiators in the care we provide. As we deliver the highest-quality, most advanced care to children and families today, it’s our research mission that unlocks the limitless possibilities of how much more we can do tomorrow. Our search for a new leader for that mission was undertaken with the deepest appreciation for the critical importance of this role.

Effective December 20, 2021, Dr. Andrews will join our Boston Children’s team, helping to write the next chapters in support of our basic science, translational and clinical research, and leading the implementation of the strategic plan that will continue to guide our research mission for years to come. Reporting to the CEO, she will work closely with our research leads, clinical and operational leadership across the enterprise, and partners beyond Boston Children’s, to strengthen the collaborative relationships that enable us to commit to even more sharing of knowledge as the world’s leader in pediatric healthcare.

It’s actually more accurate to say that Dr. Andrews will be returning to our Boston Children’s team, as she’s already well known to many of us here as a scientist, physician, teacher and leader. She completed her internship and residency in pediatrics at Boston Children’s, as well as a fellowship in pediatric hematology/oncology at Boston Children’s and Dana-Farber Cancer Institute, and a research fellowship in pediatric hematology in Stuart H. Orkin’s lab.

Throughout her training, and for many years after, she served as an attending physician in pediatric hematology and oncology as part of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

During her time with Boston Children’s, Dr. Andrews served as Chair of the Children’s Hospital Research Recruitment and Resources Committee, and as a member of both the Research Executive Committee and the Hospital Strategy Group. At Harvard Medical School, she served as Director of the Harvard-MIT MD/PhD Program, the George Richards Minot Professor of Pediatrics, and ultimately as Dean for Basic Sciences and Graduate Studies.

A researcher of the highest order, Dr. Andrews was an investigator of the Howard Hughes Medical Institute for 13 years before leaving Boston. Her research laboratory was responsible for the discovery of molecules important in mammalian iron homeostasis and identification of the molecular causes of several diseases characterized by abnormal handling of iron.

More recently, Dr. Andrews spent 10 years as a Professor in Pediatrics, Dean of the School of Medicine, and Vice Chancellor for Academic Affairs at Duke University. As dean, she led a faculty of 2,200 physicians and scientists, and a complex research enterprise supported by more than $700 million in grants and contracts annually. In addition to a long list of new initiatives, her support for research included creation of a satellite campus in the Durham Innovation District, initiation of construction of a new research building, launch of a Department of Population Health Sciences, formation of the Duke Office for Clinical Research, and establishment of MEDx, an ambitious research and education collaboration between the School of Medicine and the School of Engineering.

Dr. Andrews is an elected Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science, as well as an elected member of the National Academy of Sciences, the National Academy of Medicine, the Society for Pediatric Research and the American Pediatric Society, among other organizations. She is a past president of the American Society of Clinical Investigation, and currently serves as Chair of the Board of Directors of the American Academy of Arts and Sciences.

Dr. Andrews received her BS and MS degrees in Molecular Biophysics and Biochemistry _summa cum laude_ from Yale, her PhD in Biology from MIT, and her MD from Harvard Medical School.

I’d like to thank our EVP of Health Affairs, Peter Laussen, MBBS, FANZCA, FCICM, for leading the successful search for our new CSO, and Physician-in-Chief Gary Fleisher, MD, who has expertly guided the ship as our Interim CSO. Their guardianship of our research mission is greatly appreciated, and they will both work closely with Dr. Andrews in her transition.

Please join me in welcoming Dr. Andrews back to Boston. Her arrival at the end of December marks more than just the beginning of a new year; it signals a new era for research at Boston Children’s, and I very much look forward to seeing what’s coming next.

Warmest Regards,
Kevin B. Churchwell, MD
President and Chief Executive Officer